OrSense, a developer of monitors for non-invasive measurements of various blood parameters, has presented NBM 200 results at the XXXIst International Congress of the International Society of Blood Transfusion (ISBT). It determines that Hemoglobin (Hb) measurements obtained by the NBM 200 showed accurate performance compared with invasive point of care (POC) devices.
OrSense said that the presentation provides data of NBM 200, a non-invasive Hb measurement system for various hematological applications including anemia monitoring, hemorrhage detection and pre-donation screening.
Hb measurements allow the detection of anemia and hemorrhage, and are widely used by hospital wards such as operation rooms, ICU, ER and delivery rooms. In blood donation centers, a predonation Hb measurement of blood donors is required by most countries to protect anemic donors, and to ensure adequate Hb content of blood units.
The determination of Hb levels of prospective blood donors is usually performed using capillary blood obtained by finnger pricking, rendering current Hb screening methods invasive, painful, time consuming and labor intensive.
Paul Holland, former president of the ISBT, said: “OrSense’s non-invasive solution has the potential for improving anemia screening and monitoring by eliminating pain, reducing infection risk and enabling a simple and fast diagnosis.”
Lior Ma’ayan, CEO of OrSense, said: “Hb measurements obtained by the NBM 200 in multiple applications, showed accurate performance compared with the gold standard invasive reference values. Our non-invasive system was found to be environmentally friendly, safe, fast and easy to use by the operating staff.
“Our spot and continuous non-invasive devices, which we launched last year, are already in use for various hematological applications, improving donor and patient safety and care.”